Canaccord Genuity maintains a 'Buy' on Aegerion Pharmaceuticals (AEGR); Time For Some Answers
Tweet
Share
E-mailGet Alerts AEGR Hot Sheet
Price: $1.97 --0%
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Rating Summary:
8 Buy, 4 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 19 | New: 8
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Aegerion Pharmaceuticals (NASDAQ: AEGR) price target of $27.00.
Analyst, Salveen Richter, said, "Is increased live fat cause for concern? Hepatologist Dr. Lewis reviewed the P3 lomitapide safety, which showed a mean increase of liver fat from a baseline of 0.9% +/- 1.0% (n=23) to 9.0% +/- 7.9% (wk 26, n=22 until week 78), 7.3% +/- 8.2% (wk 56), and 8.2% (wk 78), concluding that the increase in fat is controllable and not a cause for pathologic concern given the drug appears to have a physiologic effect on the liver, but not a toxic one."
"How likely is FDA approval? Dr. Lewis and Dr. Rader both expect lomitapide to be approved by the FDA despite the liver fat increases, given that it is strongly efficacious and no P3 patients were symptomatic, discontinued lomitapide, or suffered an adverse outcome as a result of the level increases."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $15.00 yesterday.
Analyst, Salveen Richter, said, "Is increased live fat cause for concern? Hepatologist Dr. Lewis reviewed the P3 lomitapide safety, which showed a mean increase of liver fat from a baseline of 0.9% +/- 1.0% (n=23) to 9.0% +/- 7.9% (wk 26, n=22 until week 78), 7.3% +/- 8.2% (wk 56), and 8.2% (wk 78), concluding that the increase in fat is controllable and not a cause for pathologic concern given the drug appears to have a physiologic effect on the liver, but not a toxic one."
"How likely is FDA approval? Dr. Lewis and Dr. Rader both expect lomitapide to be approved by the FDA despite the liver fat increases, given that it is strongly efficacious and no P3 patients were symptomatic, discontinued lomitapide, or suffered an adverse outcome as a result of the level increases."
For an analyst ratings summary and ratings history on Aegerion Pharmaceuticals click here. For more ratings news on Aegerion Pharmaceuticals click here.
Shares of Aegerion Pharmaceuticals closed at $15.00 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nomura/Instinet Upgrades Tata Motors (TMCV:IN) to Buy
- JPMorgan Downgrades M&G PLC (MNG:LN) to Underweight
- HSBC Downgrades Universal Music Group NV (UMG:NA) (UMGNF) to Reduce
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
